Tenofovir
- PDF / 153,770 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 49 Downloads / 153 Views
1
S
Congenital pyelectasis in fetuses following in utero exposure: 2 case reports Congenital pyelectasis developed in a male fetus (patient 1) and a female fetus (patient 2) after in utero exposure to tenofovir [dosages not stated], which their mothers had received for HIV*. The mother of patient 1 started receiving combination therapy with standard doses of tenofovir, lamivudine and lopinavir/ritonavir at the eighth week of pregnancy. At pregnancy week 34, an ultrasound revealed fetal pyelectasis with a right pyelocaliceal measurement of 7mm. After birth, the neonate received prophylactic nevirapine and zidovudine. At the age of 8 months, ultrasound revealed resolution of ectasia. The mother of patient 2 had been receiving tenofovir, nevirapine and lamivudine since before pregnancy. At the 18th week of pregnancy, an ultrasound showed congenital bilateral pyelocaliceal dilatation [duration of treatment to reaction onset not stated]; ultrasound was repeated at the 27th and 32nd week of pregnancy. At last examination before caesarean delivery, the fetus had bilateral caliceal measurements of 7mm. At the age of 1 month, the neonate’s left and right renal pelvis measured 1.5cm and 1.2cm, respectively. * It was unclear whether the women were receiving tenofovir or tenofovir disoproxil fumarate. Sabbatini F, et al. Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases. Infection 35: 801079764 474-476, No. 6, Dec 2007 - Italy
0114-9954/10/1186-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 26 Jan 2008 No. 1186
Data Loading...
